NuCana plc

NCNA

Healthcare|Biotechnology|GB

$0.94

+0.00 (+0.40%)

DCF Value

$14.72

Tangible Book / Share

$4.29

Cash / Share

$4.63

Clinical Trials (7)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT03829254 A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma	Advanced Cancer, Lymphoma	P1P2	Recruiting	135	Open-label	NUC-7738, Pembrolizumab
NCT04163900 Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer	Biliary Tract Cancer	P3	Terminated	773	RCT, Single-blind	NUC-1031, Gemcitabine, Cisplatin
NCT05714553 NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	Advanced Cancer, Advanced Solid Tumor	P1P2	Terminated	19	Open-label	Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab, Docetaxel
NCT03146663 NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer	Ovarian Cancer	P2	Terminated	53	RCT, Open-label	NUC-1031 500 mg, NUC-1031 750mg
NCT05678257 A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer	Colorectal Cancer, Colorectal Neoplasms	P2	Terminated	180	RCT, Open-label	Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan, Bevacizumab, 5-FU
NCT03428958 A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment	Colorectal Cancer, Colorectal Neoplasms	P1P2	Completed	111	Open-label	NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab
NCT01621854 NUC-1031 in Patients With Advanced Solid Tumours	Cancer	P1	Completed	68	Open-label	NUC-1031